Opiate Addiction Clinical Trials
Here are the 6 most popular medical studies for opiate addiction
Behavioral Intervention
Harm Reduction Kiosk for Substance Use Disorders
This trial tests a community-tailored kiosk to reduce HIV, hepatitis C, and overdose risk in Appalachian Kentucky, an area at the center of the injection drug use, overdoses, and hepatitis C crises.
SIRI Checklist and Peer Recovery Coach for HIV Infection
This trial will develop and test a checklist to increase evidence-based treatment for rural people who use drugs, including long-acting injectable agents. The hypothesis is that hospital-based care models can successfully engage rural people in effective addiction treatment and infection prevention, which is foundational to Ending the HIV epidemic in rural states.
Behavioural Intervention
Smartphone-Assisted Prevention for Opioid Use Disorder
This trial would use apps to help prevent relapse among patients receiving treatment for opioid use disorder. The apps would track the person's location and offer targeted, personalized intervention when they enter an area at high risk for relapse.
Popular filter options for opiate addiction trials
Opioid Use Disorder Clinical Trials
View 62 Opioid Use Disorder medical studies.
Data-Driven Decision Making (DDDM) + Overdose-prevention strategies inventory for Substance Use Disorders
This trial seeks to equip overdose fatality review teams with data tools & training to help identify opportunities to prevent overdose deaths & support evidence-based prevention strategies.
Opioid Agonist
Extended-release Buprenorphine for Opioid Use Disorder
This trial will explore how well an extended-release injectable medication helps people with opioid use disorder in rural areas. It will compare it to a standard medication. Results will include patient outcomes.
Behavioral Intervention
Stigma-reduction training for Opioid Use Disorder
This trial tests a training intervention to increase rural primary care providers' willingness to prescribe buprenorphine, a medication for opioid use disorder that may reduce HIV transmission.
OUD Clinical Trials
View 58 OUD medical studies.
Data-Driven Decision Making (DDDM) + Overdose-prevention strategies inventory for Substance Use Disorders
This trial seeks to equip overdose fatality review teams with data tools & training to help identify opportunities to prevent overdose deaths & support evidence-based prevention strategies.
Opioid Agonist
Extended-release Buprenorphine for Opioid Use Disorder
This trial will explore how well an extended-release injectable medication helps people with opioid use disorder in rural areas. It will compare it to a standard medication. Results will include patient outcomes.
Behavioral Intervention
Stigma-reduction training for Opioid Use Disorder
This trial tests a training intervention to increase rural primary care providers' willingness to prescribe buprenorphine, a medication for opioid use disorder that may reduce HIV transmission.
Phase 3 Opiate Addiction Clinical Trials
View 95 phase 3 opiate addiction medical studies.
Opioid Agonist
Extended-release Buprenorphine for Opioid Use Disorder
This trial will explore how well an extended-release injectable medication helps people with opioid use disorder in rural areas. It will compare it to a standard medication. Results will include patient outcomes.
Neuromodulator Medical Device
Lofexidine + Bridge Device for Opioid Use Disorder
This trial is designed to study the efficacy of the Bridge Device, a neuromodulator medical device, for the treatment of Opioid Use Disorder. The device was cleared by the FDA based on safety, but not efficacy. The trial will enroll persons with active OUD who will be randomly assigned to one of three conditions: active BD with placebo, sham BD with lofexidine, or sham BD and placebo. The study will monitor participants for withdrawal symptoms and tolerance after device removal.
Opioid Agonist
Buprenorphine for Opioid Use Disorder in Expectant Mothers
This trial is testing whether an extended-release form of buprenorphine is as effective as the standard form in treating pregnant women with opioid use disorder, with the goal of improving outcomes for mother and child.
Opiate Addiction Clinical Trials With No Placebo
View 95 opiate addiction medical studies that do not have a placebo group.
Data-Driven Decision Making (DDDM) + Overdose-prevention strategies inventory for Substance Use Disorders
This trial seeks to equip overdose fatality review teams with data tools & training to help identify opportunities to prevent overdose deaths & support evidence-based prevention strategies.
Opioid Agonist
Extended-release Buprenorphine for Opioid Use Disorder
This trial will explore how well an extended-release injectable medication helps people with opioid use disorder in rural areas. It will compare it to a standard medication. Results will include patient outcomes.
Behavioral Intervention
FAIR for Parental Substance Use Disorder within DHS-Involved Families
“ I seen a ad on Facebook and anything that would help me be better for my daughters and myself is worth looking into in my opinion. Having support in any are in life is a plus for me as well.”
View More Opiate Addiction Trials
See another 73 many medical studies focused on opiate addiction.
Frequently Asked Questions
Introduction to opiate addiction
What are the top hospitals conducting opiate addiction research?
In the battle against opiate addiction, top hospitals across the United States are tirelessly working to develop effective treatments and interventions. One such institution is Boston Medical Center in Boston, which currently has six active clinical trials focused on opiate addiction. With a total of 11 trials conducted thus far, their commitment to tackling this crisis was evident from their inaugural trial in 2009. Another notable player in this field is the University of Kentucky located in Lexington, with five ongoing opiate addiction trials and a solid track record of nine completed studies since their first trial back in 2006.
Notably joining these renowned hospitals is Gateway Community Services based in Jacksonville. Despite having a smaller number of three active opiate addiction trials and four completed studies to its name, Gateway Community Services made significant strides by embarking on its first recorded opiate addiction trial as recent as 2020—a testament to their dedication towards combating this pressing issue.
Closer to home for some patients can be found at Massachusetts General Hospital HOPE Clinic situated within Boston itself; it shares similar progress with three current open clinical tests along-side three prior endeavors that all began further fueling research during the year2020.
Lastly but not least important among these leading institutions stands out Pregnancyate addiction, top hospitals across the United States are tirelessly working to develop effective treatments and interventions. One such institution is Boston Medical Center in Boston, which currently has six active clinical trials focused on opiate addiction. With a total of 11 trials conducted thus far, their commitment to tackling this crisis was evident from their inaugural trial in 2009. Another notable player in this field is the University of Kentucky located in Lexington, with five ongoing opiate addiction trials and a solid track record of nine completed studies since their first trial back in 2006.
Notably joining these renowned hospitals is Gateway Community Services based in Jacksonville. Despite having a smaller number of three active opiate addiction trials and four completed studies to its name, Gateway Community Services made significant strides by embarking on its first recorded opiate addiction trial as recent as 2020—a testament to their dedication towards combating this pressing issue.
Closer to home for some patients can be found at Massachusetts General Hospital HOPE Clinic situated within Boston itself; it shares similar progress with three current open clinical tests along-side three prior endeavors that all began further fueling research during the year2020.
Lastly but not least important among these leading institutions stands out Pregnancy Recovery Center at Magee-Womens Hospital of UPMC positioned firmly within Pittsburgh's healthcare landscape specializing primarily catered towards women facing opioid dependency issues; actively participating through conducting three different active investigations while completing another two previously initiated ones- each forming part integral contribution during past year itself displaying unwavering commitment providing aid & solutions needed for afflicted individuals
These remarkable hospitals symbolize hope for those grappling with opiate addiction by ensuring that innovative approaches are explored continuously. As they strive forward collectively underlining an urgent need encompassing diverse regions throughout America-it becomes clearer than ever before: The fight against opioid abuse demands our united resilience coupled together progressively forging ahead until every roadblock ceases existence
Which are the best cities for opiate addiction clinical trials?
When it comes to opiate addiction clinical trials, several cities emerge as prominent locations for research and treatment. Boston, Massachusetts takes the lead with 16 active trials investigating interventions like Buprenorphine Injection, Psilocybin, and Communities That HEAL. Following closely behind is Albuquerque, New Mexico with 10 ongoing studies focusing on approaches such as Collaborative care Plus and Substance Use Treatment and Recovery Team (START). New York City also has 10 active trials exploring treatments including Pharmacogenetic testing and Cannabidiol (CBD). Additionally, Lexington in Kentucky and Atlanta in Georgia both have 7 active trials each that examine various interventions for opiate addiction. These cities offer individuals battling this epidemic an opportunity to participate in cutting-edge clinical research aimed at finding better solutions for recovery.
Which are the top treatments for opiate addiction being explored in clinical trials?
Clinical trials are actively exploring various treatments for opiate addiction, with Buprenorphine Injection emerging as one of the top contenders. This powerful medication is currently being tested in three active trials dedicated to combatting opiate addiction. Since its first listing in 2020, it has gained attention and involvement in a total of three all-time clinical trials focused on addressing this pressing issue. As researchers delve deeper into finding effective solutions, the potential impact of Buprenorphine Injection offers hope for individuals battling opiate addiction.
What are the most recent clinical trials for opiate addiction?
Exciting developments are underway in the field of opiate addiction treatment, with recent clinical trials offering promising options for individuals seeking recovery. Among these trials is continuous intercostal nerve block (CINB), a Phase 4 study that explores its effectiveness in managing opiate addiction. Additionally, Aurora 1:1 Drops (Indica) and Liposomal Bupivacaine have shown potential benefits as interventions for opiate addiction in Phase 2 and Phase 3 trials respectively. Another important trial investigates the use of a transcutaneous cervical vagal nerve stimulation device to address opiate addiction, while ultrasound shear wave elastography examination offers insight into this complex condition through a Phase 4 study. These groundbreaking studies pave the way towards improved solutions for those grappling with opiate addiction, highlighting an encouraging path forward.
What opiate addiction clinical trials were recently completed?
The field of opiate addiction has seen several recent clinical trials reaching completion, offering new insights and potential treatments for this pressing issue. In August 2022, Indivior Inc.'s trial on INDV-2000 concluded successfully, followed closely by BioCorRx Pharmaceuticals, Inc.'s BICX104 trial in June 2022. Notably, Go Medical Industries Pty Ltd completed their Naltrexone 380 MG study in January 2021. Among earlier accomplishments is the December 2020 completion of a Ketamine Hydrochloride trial led by the Medical University of South Carolinae addiction has seen several recent clinical trials reaching completion, offering new insights and potential treatments for this pressing issue. In August 2022, Indivior Inc.'s trial on INDV-2000 concluded successfully, followed closely by BioCorRx Pharmaceuticals, Inc.'s BICX104 trial in June 2022. Notably, Go Medical Industries Pty Ltd completed their Naltrexone 380 MG study in January 2021. Among earlier accomplishments is the December 2020 completion of a Ketamine Hydrochloride trial led by the Medical University of South Carolina and an Emory University-led Non invasive VN stimulation (nVNS) trial in November 2020. NYU Langone Health's Buprenorphine Naloxone study also concluded that same month. While Jacques E. Chelly's Ketamine trial wrapped up in December 2019 and Alar Pharmaceuticals Inc.'s ALA-1000 study reached its end point in September of that year.